Sept 21 (Reuters) - Liminal BioSciences Inc LMNL.O :
* LIMINAL BIOSCIENCES PROVIDES UPDATE ON PROGRESS ON BLA FOR RYPLAZIM®(PLASMINOGEN)
* LIMINAL BIOSCIENCES - FDA CONFIRMED THAT RESUBMISSION IS A COMPLETE, CLASS 2 RESPONSE AND HAS PROVIDED A PDUFA TARGET ACTION DATE OF MARCH 5, 2021
* LIMINAL BIOSCIENCES - FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION, BY ITS U.S. SUBSIDIARY, PROMETIC BIOTHERAPEUTICS INC., OF BLA FOR RYPLAZIM
* LIMINAL BIOSCIENCES - SEES POTENTIAL APPROVAL AND COMMERCIAL LAUNCH OF RYPLAZIM IN U.S. IN 2021